OCUGEN INC. - COMMON

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

13 6 2022 06:00:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at BIO International Convention 2022

09 6 2022 17:17:10 提供 Nasdaq GlobeNewswire

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

24 5 2022 06:11:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

23 5 2022 06:34:00 提供 Nasdaq GlobeNewswire

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

23 5 2022 05:36:00 提供 Nasdaq GlobeNewswire

Ocugen Provides Business Update and First Quarter 2022 Financial Results

06 5 2022 05:33:00 提供 Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

02 5 2022 06:37:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

29 4 2022 10:36:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

25 4 2022 06:33:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at NobleCon18

19 4 2022 16:32:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

18 4 2022 06:11:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

12 4 2022 07:31:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

01 4 2022 06:37:00 提供 Nasdaq GlobeNewswire

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

23 3 2022 06:44:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

21 3 2022 17:36:00 提供 Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 3 2022 16:56:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

09 3 2022 06:11:00 提供 Nasdaq GlobeNewswire

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

04 3 2022 06:01:00 提供 Nasdaq GlobeNewswire

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

25 2 2022 06:31:00 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

22 2 2022 20:43:33 提供 Nasdaq GlobeNewswire